Metropolis Healthcare Latest Updates

Financial Performance Metropolis Healthcare has demonstrated strong financial performance, with an unaudited revenue increase of approximately 23% year-on-year for the quarter ending June 30, 2025. This growth was driven by higher patient and test volumes, as well as the positive impact of recent acquisitions. The company's specialty revenues, in particular, grew by up to 35% YoY. Metropolis has also stated that it is debt-free. The board is scheduled to meet on August 7, 2025, to formally approve the financial results for the quarter. Strategic Expansion The company is actively pursuing an acquisition-led growth strategy to expand its market presence, particularly in North and East India. A key recent acquisition was Core Diagnostics, a specialized player in oncology testing, which has significantly boosted Metropolis's capabilities in high-end diagnostics. Other recent acquisitions include Scientific Pathology in Agra and Dr. Ahuja's Pathology & Imaging Centre (DAPIC) in Uttarakhand, which have further strengthened its footprint and consumer base in these micro-markets. Stock and Market Outlook Metropolis Healthcare's stock has shown some positive momentum, breaking out of a recent two-month consolidation phase. While analysts note the stock is trading at a premium valuation, they see potential for an upward movement. The company will be holding an earnings conference call on August 8, 2025, to discuss its financial results and future outlook with investors.